REGENERON PHARMACEUTICALS, INC. 10-Q

Item 5. Other Information As disclosed in the table below, during the three months ended March 31, 2024, certain of our directors and/or executive officers adopted plans for trading arrangements intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act. Name Position Date of Plan Adoption Scheduled End Date of Trading Arrangement (a) Total Number of Securities to Be Sold Under the Plan Bonnie L. Bassler, Ph.D. Director 2/27/2024 4/30/2025 3,851 Michael S. Brown, M.D. Director 2/26/2024 8/31/2024 2,707 Joseph J. LaRosa Executive Vice President, General Counsel and Secretary 2/16/2024 2/10/2025 5,191 Marion McCourt Executive Vice President, Commercial 2/13/2024 5/31/2025 8,122 Leonard S. Schleifer, M.D., Ph.D. Board co-Chair, President and Chief Executive Officer 2/5/2024 8/5/2025 229,204 George D. Yancopoulos, M.D., Ph.D. Board co-Chair, President and Chief Scientific Officer 2/14/2024 2/10/2025 100,000 (a) In each case, the trading arrangement may expire on an earlier date if and when all transactions under the arrangement are completed. 77 Table of Contents Item 6. Exhibits (a) Exhibits Exhibit Number Description 10.1* Amendment No. 2 to Master Agreement, dated as of March 7 , 202 4 , by and between Regeneron Pharmace uticals , Inc. (the "Registrant") and Alnylam Pharmaceuticals, Inc. 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934. 32 Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350. 101 Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL"): (i) the Registrant's Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023; (ii) the Registrant's Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2024 and 2023; (iii) the Registrant's Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2024 and 2023; (iv) the Registrant's Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023; and (v) the notes to the Registrant's Condensed Consolidated Financial Statements. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). * Certain confidential portions of this Exhibit were omitted in accordance with Item 601(b)(10) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of all confidential portions of this Exhibit that were omitted to the SEC upon its request. 78 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. REGENERON PHARMACEUTICALS, INC. Date: May 2, 2024 By: /s/ Christopher Fenimore Christopher Fenimore Senior Vice President, Finance and Chief Financial Officer (Duly Authorized Officer) 79